Geminin as a molecular target for the development of new anticancer drugs.
The unique biological properties of Geminin, particularly as an inhibitor of DNA replication initiation, have been recognized, and this has prompted a number of investigations into this molecule to explore its potential therapeutic as well as diagnostic usefulness. This review summarizes the possibility of Geminin serving as a new molecular target in the development of new anticancer drugs.
Yoshida
Kenichi
K
Department of Life Sciences, Meiji University, Kanagawa 214-8571, Japan. yoshida@isc.meiji.ac.jp
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002453:Cell Cycle / Q000502:physiology; D018797:Cell Cycle Proteins / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D015195:Drug Design; D064248:Geminin; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D011487:Protein Conformation
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; C577995:GMNN protein, human; D064248:Geminin